Heinz Gisslinger

13PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersCell physiologyRegenerative medicine (incl. stem cells)Haematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 06, 2025
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera.

Tiziano Barbui, Arianna Ghirardi, Victoria Empson

|Jul 27, 2025
A Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia.

Tiziano Barbui, Jürgen Thiele, Arianna Ghirardi

|Dec 05, 2023
Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials

Heinz Gisslinger

|Oct 30, 2023
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.

Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano

|Feb 23, 2023
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.

Daniel Ivanov, Jelena D Milosevic Feenstra, Irina Sadovnik

|Jan 11, 2022
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.

Jelena D Milosevic Feenstra, Roland Jäger, Fiorella Schischlik

Pageof 3

Frequent Collaborators

3 joint publications

Jelena D Milosevic Feenstra

3 joint publications

Alessandra Iurlo

3 joint publications

Alessandro Maria Vannucchi

2 joint publications

Tiziano Barbui